ArticleClinical cancer research : an official journal of the American Association for Cancer Research2018
A Rationally Designed Fully Human EGFRvIII:CD3-Targeted Bispecific Antibody Redirects Human T Cells to Treat Patient-derived Intracerebral Malignant Glioma.
Open access · bronzeAbstract read
In one paragraph
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 1 pooled it
2.9field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.
- Checkpoint inhibitor immunotherapy for glioblastoma: current progress, challenges and future outlook.Expert review of clinical pharmacology · 2020Pooled it
- Review
- Fully Humanized Bispecific T Cell Engager Shows Potent Activity in Central Nervous System and Peripheral Tumors.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Glioma tumor microenvironment and immunotherapy: past, present, and future.Biomarker research · 2025Review
- Bi-specific T cell-engaging antibody triggers protective immune memory and glioma microenvironment remodeling in immune-competent preclinical models.Journal for immunotherapy of cancer · 2025Article
- From Molecular Precision to Clinical Practice: A Comprehensive Review of Bispecific and Trispecific Antibodies in Hematologic Malignancies.International journal of molecular sciences · 2025Review
- IL-7-mediated expansion of autologous lymphocytes increases CD8bioRxiv : the preprint server for biology · 2025Article
- Bispecific Antibodies in Glioblastoma: Mechanistic Advances, Delivery Innovations, and Translational Challenges in Overcoming Immune Escape.International journal of medical sciences · 2025Review
- Immunotherapy in Glioblastoma.Cancer treatment and research · 2025Review
- Expression of EGFRvIII and its co‑expression with wild‑type EGFR, or putative cancer stem cell biomarkers CD44 or EpCAM are associated with poorer prognosis in patients with hepatocellular carcinoma.Oncology reports · 2024Article
- Potent antitumor activity of a bispecific T-cell engager antibody targeting the intracellular antigen KRAS G12V.Biomolecules & biomedicine · 2024Article
- Bispecific T-Cell Engagers and Chimeric Antigen Receptor T-Cell Therapies in Glioblastoma: An Update.Current oncology (Toronto, Ont.) · 2023Review
- Novel Immunotherapeutic Approaches for the Treatment of Glioblastoma.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2023Review
- A CD19-Anti-ErbB2 scFv Engager Protein Enables CD19-Specific CAR T Cells to Eradicate ErbB2Cells · 2023Article
- Pediatric brain tumors: a bibliometric analysis.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2022Article
- Oncolytic virus-mediated expansion of dual-specific CAR T cells improves efficacy against solid tumors in mice.Science translational medicine · 2022Article
- Designing Clinical Trials for Combination Immunotherapy: A Framework for Glioblastoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Review
- New Approaches to Glioblastoma.Annual review of medicine · 2022Review
- Current landscape and future directions of bispecific antibodies in cancer immunotherapy.Frontiers in immunology · 2022Review
- Glioblastoma Microenvironment: From an Inviolable Defense to a Therapeutic Chance.Frontiers in oncology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 1 institution in 1 country.
Patrick C GedeonDuke Brain Tumor Immunotherapy Program, Department of Neurosurgery, Duke University Medical Center, Durham, North Carolina.ORCID 0000-0002-5387-1833
Teilo H SchallerDuke Brain Tumor Immunotherapy Program, Department of Neurosurgery, Duke University Medical Center, Durham, North Carolina.
Satish K ChitneniDepartment of Radiology, Duke University Medical Center, Durham, North Carolina.ORCID 0000-0003-1183-2286
Bryan D ChoiDuke Brain Tumor Immunotherapy Program, Department of Neurosurgery, Duke University Medical Center, Durham, North Carolina.
Chien-Tsun KuanDuke Brain Tumor Immunotherapy Program, Department of Neurosurgery, Duke University Medical Center, Durham, North Carolina.
Carter M SuryadevaraDuke Brain Tumor Immunotherapy Program, Department of Neurosurgery, Duke University Medical Center, Durham, North Carolina.
David J SnyderDuke Brain Tumor Immunotherapy Program, Department of Neurosurgery, Duke University Medical Center, Durham, North Carolina.
Robert J SchmittlingDuke Brain Tumor Immunotherapy Program, Department of Neurosurgery, Duke University Medical Center, Durham, North Carolina.
Scott E SzafranskiDuke Brain Tumor Immunotherapy Program, Department of Neurosurgery, Duke University Medical Center, Durham, North Carolina.
Xiuyu CuiDuke Brain Tumor Immunotherapy Program, Department of Neurosurgery, Duke University Medical Center, Durham, North Carolina.
Patrick N HealyDepartment of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, North Carolina.
James E HerndonDepartment of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, North Carolina.
Roger E McLendonDepartment of Pathology, Duke University Medical Center, Durham, North Carolina.
Stephen T KeirDuke Brain Tumor Immunotherapy Program, Department of Neurosurgery, Duke University Medical Center, Durham, North Carolina.
Gary E ArcherDuke Brain Tumor Immunotherapy Program, Department of Neurosurgery, Duke University Medical Center, Durham, North Carolina.
Elizabeth A ReapDuke Brain Tumor Immunotherapy Program, Department of Neurosurgery, Duke University Medical Center, Durham, North Carolina.
Luis Sanchez-PerezDuke Brain Tumor Immunotherapy Program, Department of Neurosurgery, Duke University Medical Center, Durham, North Carolina.
Darell D BignerDuke Brain Tumor Immunotherapy Program, Department of Neurosurgery, Duke University Medical Center, Durham, North Carolina.
John H SampsonDuke Brain Tumor Immunotherapy Program, Department of Neurosurgery, Duke University Medical Center, Durham, North Carolina. john.sampson@duke.edu.
Duke University · US
Funding
MEDICAL SCIENTIST TRAINING PROGRAMT32GM007171 · NIGMS · DUKE UNIVERSITY · PI KONTOS, CHRISTOPHER D · 1985 to 2021
$31.2MMedical Scientist Training Program Training GrantT32GM145449 · NIGMS · DUKE UNIVERSITY · PI Christopher D Kontos · 2022 to 2026
$6.6MHuman EGFRvIII-specific BiTE for the treatment of GlioblastomaU01NS090284 · NINDS · DUKE UNIVERSITY · PI SAMPSON, JOHN H. · 2015 to 2019
$5.2MBrain tumors with regulatory T-cells treated with EGFRvIII-specific T-cellsR01CA177476 · NCI · DUKE UNIVERSITY · PI SAMPSON, JOHN H. · 2013 to 2017
$2.3MEGFRvIII-targeted Bispecific T cell Engagers for brain tumorsR01NS085412 · NINDS · DUKE UNIVERSITY · PI SAMPSON, JOHN H. · 2013 to 2017
$2.0MCCL3 as a Developmental Therapeutic to Enhance Brain Tumor TherapyR01NS099463 · NINDS · DUKE UNIVERSITY · PI SAMPSON, JOHN H. · 2017 to 2021
$1.7MBrain Tumor Targeting Using Tumor-Specific NeuroimmunologyR01NS086943 · NINDS · DUKE UNIVERSITY · PI SAMPSON, JOHN H., YAN, HAI · 2014 to 2017
$1.4MSystemic EGFRvIII-targeted bispecific antibody as immunotherapy for glioblastomaF30CA196199 · NCI · DUKE UNIVERSITY · PI GEDEON, PATRICK C · 2015 to 2018
$165kNCI NIH HHS F30 CA196199NCI NIH HHS R01 CA177476NIGMS NIH HHS T32 GM007171NIGMS NIH HHS T32 GM145449NINDS NIH HHS R01 NS085412NINDS NIH HHS R01 NS086943NINDS NIH HHS R01 NS099463NINDS NIH HHS U01 NS090284
Abstract
PubMed holds no abstract for this paper.
Indexed as
ImmunotherapyAnimalsAntibodies, BispecificCD3 ComplexCell Line, TumorErbB ReceptorsFemaleGene Expression Regulation, NeoplasticGliomaHumansLymphocyte ActivationMaleMiceRecombinant ProteinsSingle-Chain AntibodiesT-LymphocytesAntibodies, BispecificCD3 Complexepidermal growth factor receptor VIIIErbB ReceptorsRecombinant ProteinsSingle-Chain Antibodies
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.